Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, 17 May 2018. Nuevolution AB (publ) (NUE.ST) today announced the publication of the scientific article entitled "Small Molecule Positive Allosteric Modulators of the β2-Adrenergic Receptor Isolated from DNA Encoded Libraries" in the journal Molecular Pharmacology.
The new article presents further exciting work from the ongoing collaboration between Nuevolution and the group of Nobel Laureate Dr. Robert J. Lefkowitz at Duke University involving the screening of Nuevolution compound libraries against an important class of targets named GPCRs. The new publication extends our previous joint publication from 2017 now showing the identification of compounds capable of stimulating signaling across a cell membrane by a key GPCR.
"We have a very strong collaboration with the world-leading group of Dr. Lefkowitz' and we are happy to see yet another great publication from this joint work and to showcase the capability of our technology on GPCR receptors" said Thomas Franch, CSO of Nuevolution and continued "The two joint publications identifying both negative and positive allosteric GPCR modulators really open up novel future opportunities for identifying drug candidates against many GPCR's relevant for human diseases".
For more information, please contact:
Johnny Stilou, Director of investor relations
Phone: +45 8877 5973
Email: jost@nuevolution.com
Thomas Franch, CSO
Phone: +45 7020 0987
Email: tf@nuevolution.com
About Chemetics™
The Nuevolution Chemetics™ technology comprises proprietary methods enabling DNA-encoding of fragments and combinatorial chemistry libraries for fast and cost efficient screening of disease targets. Nuevolution annually produces 4-8 Chemetics™ libraries comprising millions to multi billions of compounds per library. For further details about Chemetics™, please visit: www.nuevolution.com.
About Nuevolution
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
The information was sent for publication, through the agency of the contact persons set out above, on Thursday 17 May 2018 at 14:00 CET.
Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.